Paul Hughes
Marietta, GANPI 1962943209
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $607, more than ten times the $52 reported in 2021.
Across 70 payments — averaging $23.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$223
- Novartis$199
- AstraZeneca$140
- AbbVie$134
- Sanofi$107
- Regeneron Healthcare Solutions, Inc.$107
- plus $728 from 14 others
What the payments were for
- Food & beverage$1,638100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 11 | $223 |
| Novartis | 11 | $199 |
| AstraZeneca(2 entities) | 5 | $140 |
| AbbVie | 6 | $134 |
| Sanofi | 4 | $107 |
| Regeneron Healthcare Solutions, Inc. | 4 | $107 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $101 |
| Amgen | 4 | $86 |
| Pfizer | 4 | $83 |
| Genentech, Inc. | 1 | $82 |
| GSK | 3 | $73 |
| Pharmacosmos Therapeutics Inc. | 2 | $72 |
| Genentech USA, Inc. | 3 | $68 |
| Syndax Pharmaceuticals, Inc. | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Melinta Therapeutics, LLC | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Octapharma USA, Inc. | 1 | $20 |
| Janssen Scientific Affairs, LLC | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $15 |
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.